Overall, we found Foretinib and Ponatinib to be effective in most of metastatic cancer cell lines compared to primary tumour cell lines, suggesting therapies to target FGFR1 in metastatic cancer (Fig. 5d). The gene discussed is FGFR1; the disease is metastatic malignant neoplasm.